# Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures

> **NCT06720350** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Marmara University** · enrollment: 60 (estimated)

## Conditions studied

- Osteoporosis in Post-menopausal Women

## Interventions

- **DRUG:** Romosozumab and Denosumab Combination Therapy
- **DRUG:** Romosozumab Prefilled Syringe [Evenity]
- **DRUG:** Denosumab (Prolia)

## Key facts

- **NCT ID:** NCT06720350
- **Lead sponsor:** Marmara University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-15
- **Primary completion:** 2026-10-15
- **Final completion:** 2026-12-15
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06720350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06720350, "Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06720350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*